Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Optimizing CML Management: Shared Decision Making and Enhancing the Patient Experience : Episode 2

      Navigating CML: Tools to Empower Patients and Caregivers

      July 31, 2024
      By Jorge E. Cortes, MD
      Joannie Clements
      • Claire Saxton

      Opinion
      Video

      Joannie Clements, a patient advocate, provides insights on helping newly diagnosed patients with CML and their caregivers navigate the complexities of diagnosis, and Claire Saxton outlines resources available for them.

      EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment

      Now Viewing

      EP: 2.Navigating CML: Tools to Empower Patients and Caregivers

      EP: 3.Empowering CML Caregivers: Strategies and Support Systems

      EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes

      EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life

      EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

      EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy

      EP: 8.Ensuring Informed CML Care from Diagnosis Onward

      EP: 9.Advancing CML Management Towards an Ideal Patient Journey

      This program was made possible with support from Novartis Pharmaceuticals.

      Video content above is prompted by the following questions:

      • As a patient advocate, how do you help newly diagnosed CML patients and their caregivers navigate the complexities of the diagnosis and set appropriate care goals? What are some of the biggest challenges patients may face at this stage?
      • What resources or educational materials have you found most helpful in supporting newly diagnosed CML patients and their caregivers?
        • How do patients typically use these materials? How have you changed your approaches so patients and caregivers can best leverage these materials?

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      Related Content

      Graphic depicting red blood cells

      Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM

      Bridget Hoyt
      July 25th 2025
      Article

      A generic version of ibrutinib was granted tentative approval by the FDA for use in CLL and SLL with 17p deletion and Waldenström macroglobulinemia.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic of a leukemia cell

      FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel

      Chris Ryan
      June 28th 2025
      Article

      The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.


      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      December 1st 2023
      Podcast

      Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.


      Illustration of two medical workers holding up a magnifying glass to a cross-section of a bone

      Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment

      Bridget Hoyt
      June 21st 2025
      Article

      Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.


      Graphic of bone marrow cells with cancer

      Anemia Protocol Does Not Reduce Ruxolitinib Efficacy in Myelofibrosis

      Ariana Pelosci
      June 20th 2025
      Article

      Adding danazol or erythropoiesis-stimulating agents for anemia management to a ruxolitinib regimen for myelofibrosis does not decrease treatment efficacy.

      Related Content

      Graphic depicting red blood cells

      Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM

      Bridget Hoyt
      July 25th 2025
      Article

      A generic version of ibrutinib was granted tentative approval by the FDA for use in CLL and SLL with 17p deletion and Waldenström macroglobulinemia.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic of a leukemia cell

      FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel

      Chris Ryan
      June 28th 2025
      Article

      The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.


      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      December 1st 2023
      Podcast

      Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.


      Illustration of two medical workers holding up a magnifying glass to a cross-section of a bone

      Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment

      Bridget Hoyt
      June 21st 2025
      Article

      Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.


      Graphic of bone marrow cells with cancer

      Anemia Protocol Does Not Reduce Ruxolitinib Efficacy in Myelofibrosis

      Ariana Pelosci
      June 20th 2025
      Article

      Adding danazol or erythropoiesis-stimulating agents for anemia management to a ruxolitinib regimen for myelofibrosis does not decrease treatment efficacy.

      Latest Conference Coverage

      Understanding How On-Target and Off-Target ADC Toxicities Work

      Monitoring for Infection-Like AEs Is Essential for CIML NK in GI Cancers

      Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.